Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.000
-0.175 (-5.51%)
May 7, 2026, 11:48 AM EDT - Market open
Editas Medicine Revenue
Editas Medicine had revenue of $2.83M in the quarter ending March 31, 2026, a decrease of -39.22%. This brings the company's revenue in the last twelve months to $38.69M, up 7.97% year-over-year. In the year 2025, Editas Medicine had annual revenue of $40.52M with 25.39% growth.
Revenue (ttm)
$38.69M
Revenue Growth
+7.97%
P/S Ratio
8.03
Revenue / Employee
$444,747
Employees
87
Market Cap
293.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.52M | 8.21M | 25.39% |
| Dec 31, 2024 | 32.31M | -45.81M | -58.64% |
| Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
| Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
| Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
| Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
| Dec 31, 2019 | 20.53M | -11.41M | -35.71% |
| Dec 31, 2018 | 31.94M | 18.21M | 132.64% |
| Dec 31, 2017 | 13.73M | 7.68M | 126.80% |
| Dec 31, 2016 | 6.05M | 4.42M | 271.58% |
| Dec 31, 2015 | 1.63M | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zentalis Pharmaceuticals | 26.87M |
| LENZ Therapeutics | 19.09M |
| Armata Pharmaceuticals | 4.90M |
| AC Immune | 4.62M |
| Compass Therapeutics | 850.00K |
| Artiva Biotherapeutics | 251.00K |
EDIT News
- 2 days ago - Editas Medicine reports Q1 EPS (26c), consensus (24c) - TheFly
- 2 days ago - Editas Medicine Announces First Quarter 2026 Results and Business Updates - GlobeNewsWire
- 9 days ago - Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences - GlobeNewsWire
- 24 days ago - Editas Medicine price target raised to $15 from $13 at Evercore ISI - TheFly
- 5 weeks ago - Editas Medicine announces USPTO reaffirms prior decision on CRISPR/Cas9 patents - TheFly
- 5 weeks ago - Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference - GlobeNewsWire
- 2 months ago - Editas Medicine Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 2 months ago - Editas Medicine upgraded to Buy from Hold at JonesResearch - TheFly